FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance

[1]  Fengzhi Li,et al.  FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX. , 2014, Cancer research.

[2]  Fengzhi Li.  Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer? , 2014, American journal of cancer research.

[3]  Fengzhi Li,et al.  Antitumor activity of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration. , 2014, Molecular pharmaceutics.

[4]  V. Patriarca,et al.  Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models , 2012, Cancer Chemotherapy and Pharmacology.

[5]  Fengzhi Li,et al.  A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity , 2012, PloS one.

[6]  T. Gauler,et al.  A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Causse,et al.  New Topoisomerase I mutations are associated with resistance to camptothecin , 2011, Molecular Cancer.

[8]  A. Ohtsu,et al.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.

[9]  G. Szakács,et al.  Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.

[10]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[11]  Sunhwan Jo,et al.  PBEQ-Solver for online visualization of electrostatic potential of biomolecules , 2008, Nucleic Acids Res..

[12]  E. Shin,et al.  Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancer , 2007, Cancer.

[13]  A. Ohtsu,et al.  Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912) , 2007 .

[14]  Mitchell Ho,et al.  Mesothelin Expression in Human Lung Cancer , 2007, Clinical Cancer Research.

[15]  Y. Pommier.  Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.

[16]  E. Shin,et al.  Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. V. Von Hoff,et al.  Hydrophilic Camptothecin Analogs That Form Extremely Stable Cleavable Complexes with DNA and Topoisomerase I , 2004, Cancer Research.

[18]  T. Ishikawa,et al.  Novel camptothecin analogues that circumvent ABCG2‐associated drug resistance in human tumor cells , 2004, International journal of cancer.

[19]  G. Kéri,et al.  High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. , 2004, Molecular pharmacology.

[20]  Y. Pommier,et al.  ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan‐treated metastases , 2004, International journal of cancer.

[21]  Fengzhi Li,et al.  Induction of Survivin Expression by Taxol (Paclitaxel) Is an Early Event, Which Is Independent of Taxol-mediated G2/M Arrest* , 2004, Journal of Biological Chemistry.

[22]  E. L. Volk,et al.  Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.

[23]  S. Bates,et al.  Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. , 2003, Cancer research.

[24]  M. Hawkins,et al.  Bryostatin-I—An Antineoplastic Treasure from the Deep? , 2002, Cancer biology & therapy.

[25]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[26]  Masahiro Fukuoka,et al.  Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. , 2002, Lung cancer.

[27]  T. Ishikawa,et al.  Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. , 2001, Biochemical and biophysical research communications.

[28]  T. Litman,et al.  Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.

[29]  A. Ferrari,et al.  Novel 7-substituted camptothecins with potent antitumor activity. , 2000, Journal of medicinal chemistry.

[30]  M. Kuo,et al.  BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. , 2000, Biochemical pharmacology.

[31]  Hanqing Wu.  Chemical Property Calculation through JavaScript and Applications in QSAR , 1999 .

[32]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Bjornsti,et al.  A Camptothecin-resistant DNA Topoisomerase I Mutant Exhibits Altered Sensitivities to Other DNA Topoisomerase Poisons (*) , 1995, The Journal of Biological Chemistry.

[34]  S. Sawada,et al.  Chemical modification of an antitumor alkaloid camptothecin: synthesis and antitumor activity of 7-C-substituted camptothecins. , 1991, Chemical & pharmaceutical bulletin.

[35]  R. Hertzberg,et al.  On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. , 1989, Biochemistry.

[36]  Shozo Masuda,et al.  REVISED METHOD FOR CALCULATION OF GROUP ELECTRONEGATIVITIES , 1982 .

[37]  James E. Huheey,et al.  The Electronegativity of Multiply Bonded Groups , 1966 .

[38]  James E. Huheey,et al.  The Electronegativity of Groups , 1965 .

[39]  Fengzhi Li,et al.  An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). , 2013, American journal of translational research.

[40]  Y. Pommier,et al.  Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex , 2005, Cancer Chemotherapy and Pharmacology.

[41]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Ross,et al.  Reversal of breast cancer resistance protein (BCRP/ABCG2)‐mediated drug resistance by novobiocin, a coumermycin antibiotic , 2004, International journal of cancer.

[43]  L. Liu,et al.  Tumor cell death induced by topoisomerase-targeting drugs. , 2001, Annual review of pharmacology and toxicology.